Trial Profile
Pembrolizumab and Radiation for Locally Advanced Squamous Cell Carcinoma of the Head and Neck (SCCHN) Not Eligible for Cisplatin Therapy
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 11 Jan 2024
Price :
$35
*
At a glance
- Drugs Pembrolizumab (Primary)
- Indications Head and neck cancer; Squamous cell cancer
- Focus Therapeutic Use
- 15 Dec 2023 Status changed from active, no longer recruiting to completed.
- 03 Mar 2023 Planned End Date changed from 30 Jul 2023 to 30 Nov 2023.
- 03 Mar 2023 Planned primary completion date changed from 30 Jul 2023 to 30 Nov 2023.